CEL-SCI Corporation 

(Public, AMEX:CVM)   Watch this stock   
Find more results for CVM
Sep 14, 2009
Shareholders Meeting
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -21940.00% -154100.00%
Operating margin -12193.33% -190260.00%
EBITD margin - -184340.00%
Return on average assets -161.00% -43.51%
Return on average equity -254.56% -63.74%
Employees 30 -

Address

8229 Boone Boulevard Suite 802
Vienna, VA 22182
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

CEL-SCI Corporation discussed on blogs

November 23rd CEOcast Weekly Newsletter : Stock-Profiles.com - CEOCastNews - Stock-Profiles.com - 6 hours ago

CEL-SCI Corporation discussions

  View all discussions »

Description

CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is immunotherapy, incorporating both active and passive immune activity.

Officers and directors

Geert R. Kersten
Chief Executive Officer, Treasurer, Director
Age: 50
Bio & Compensation - Reuters
Patricia B. Prichep
Senior Vice President - Operations, Secretary
Age: 58
Bio & Compensation - Reuters
Eyal Talor Ph.D.
Senior Vice President - Research and Manufacturing
Age: 53
Bio & Compensation - Reuters
Maximilian De Clara
President, Director
Age: 79
Bio & Compensation - Reuters
Alexander G. Esterhazy
Director
Age: 66
Bio & Compensation - Reuters
C. Richard Kinsolving Ph.D.
Director
Age: 72
Bio & Compensation - Reuters
Peter R. Young Ph.D.
Director
Age: 64
Bio & Compensation - Reuters